Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics – An evidence-based overview for decision makers
Open Access
- 7 September 2025
- journal article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 59 (11) , 950-956
Abstract
Psychotropic pharmacogenetics (PGx) offers significant potential advancements in psychiatric care by optimising medication selection and dosing based on genetic factors. This perspective article highlights the clinical utility, health economic implications and implementation challenges of psychotropic PGx, proposing that its broader implementation could enhance patient outcomes and reduce healthcare costs. Landmark studies show that PGx-guided care results in fewer adverse drug reactions and improved medication efficacy, with substantial cost savings compared to traditional prescribing methods. However, implementation barriers persist, particularly in Australia, where knowledge gaps, limited clinical guidelines and funding constraints hinder adoption. Despite challenges such as industry bias and limited data on non-antidepressant psychotropics, robust clinical and economic evidence supports the expanded use of psychotropic PGx, with emerging combinatorial approaches offering promise for future psychiatric treatment.Keywords
This publication has 65 references indexed in Scilit:
- Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted TherapyClinical Pharmacology & Therapeutics, 2024
- Clinical implementation of preemptive pharmacogenomics in psychiatryEBioMedicine, 2024
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor AntidepressantsClinical Pharmacology & Therapeutics, 2023
- ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 StudyClinical Pharmacology & Therapeutics, 2023
- Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical TrialsClinical Pharmacology & Therapeutics, 2022
- Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal PerspectiveClinical Drug Investigation, 2022
- Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive DisorderJAMA, 2022
- Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With SchizophreniaJAMA Network Open, 2020
- ABCB1 gene variants and antidepressant treatment outcome: A meta‐analysisAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015
- Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A systematic reviewEuropean Neuropsychopharmacology, 2013